Roche enters merger agreement to acquire PathAI and expand AI‑driven diagnostics capabilities

Roche has entered into a definitive merger agreement to acquire PathAI, a US-based leader in digital pathology and AI-powered technology for pathology laboratories and the biopharma industry.

The transaction is expected to close in the second half of the year, subject to customary closing conditions, including antitrust and regulatory approvals. The acquisition aims to transform AI-driven diagnostics, accelerate personalized healthcare, and strengthen Roche’s global position in digital pathology and companion diagnostics.

Building on a strategic digital pathology partnership

Roche and PathAI have collaborated since 2021, with the partnership expanded in 2024 to include the development of AI-enabled companion diagnostic algorithms. Under the terms of the new merger agreement, the acquired entity will become part of Roche’s Diagnostics division once the transaction closes.

The acquisition is designed to integrate PathAI’s advanced AI platform and digital pathology capabilities with Roche’s established diagnostics portfolio, enhancing the development of clinical therapies, enabling the discovery of new biomarkers, and supporting the creation of novel diagnostic tools.

Advancing digital pathology and AI-driven workflows

Digital pathology is transforming traditionally manual pathology workflows into fully automated, AI-driven processes. By converting physical tissue samples on slides into high-resolution digital images, pathologists can apply AI tools to streamline diagnostic workflows and deliver faster results to patients.

This acquisition strengthens Roche’s position in digital pathology by combining its existing platforms with PathAI’s best-in-class Image Management System (IMS). The integration is expected to drive laboratory efficiency, improve diagnostic precision, and support the shift from broad intervention to more personalized healthcare.

PathAI’s AISight IMS to enhance Roche’s digital pathology portfolio

PathAI’s AISight IMS software interface is designed to be efficient and user-friendly, integrating advanced AI analysis and workflow capabilities directly into the digital pathology laboratory. In the rapidly growing global pathology market, Roche intends to scale this solution worldwide as part of its digital pathology portfolio.

By combining Roche’s oncology and companion diagnostics platforms with PathAI’s AISight IMS and AI algorithms, laboratories will be able to optimize image management, standardize workflows, and support more consistent, data-driven diagnostic decisions.

Strengthening precision medicine and biopharma services

The expanded capabilities resulting from this acquisition are expected to enhance Roche’s competitiveness in precision medicine and its services for biopharma partners. PathAI’s AI-driven solutions, which include clinical trial support and translational research, will complement Roche’s deep expertise in companion diagnostics.

Together, Roche and PathAI aim to foster the discovery of new biomarkers, identify potential drug targets, and develop novel diagnostic tools. These integrated capabilities are intended to increase the value Roche can deliver to biopharma companies and accelerate the development of targeted therapies for patients.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>